Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter ...

google.com·1w

Active Biotech Interim Report Q1 2026

google.com·2w

Hospital Authority expands subsidy for blood cancer drugs

google.com·2w

High-dose ruxolitinib (25 mg twice daily) in myelofibrosis : feasibility, safety, and long-term ...

google.com·2w

Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens

google.com·2w

Regulatory actions for May 5, 2026

google.com·2w

Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer

google.com·2w

White Blood Cell Count as Independent Thrombotic Risk Factor and Symptom Burden Assessment

google.com·2w

Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis

google.com·2w

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

google.com·2w

Myelofibrosis Therapeutics Market to Reach US$ 7.63 Billion

google.com·2w

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative ...

google.com·2w

Myelofibrosis Pipeline Set for Breakthrough Expansion by 2026

google.com·2w

Spotlighting the Nuances of the SERENA-6 Trial Design Following the FDA's ODAC Vote

google.com·2w

Navigating JAK Inhibitors and Transplant in Myelofibrosis

google.com·2w

In-Depth Analysis of Segments, Industry Trends, and Key

google.com·2w

Jakafi XR Approved for Myelofibrosis , Polycythemia Vera , and GVHD - MPR

google.com·2w

FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions

google.com·2w

Karyopharm (KPTI) Q1 2025 Earnings Transcript

google.com·2w

FDA Approves Extended-Release Ruxolitinib Once-Daily for MPNs and GVHD

google.com·2w

Log in to enable infinite scrolling